Poseida therapeutics highlights positive interim phase 1 results for p-bcma-allo1 and preclinical data for dual car-t p-cd19cd20-allo1 at the 66th american society of hematology (ash) annual meeting

Additional new profiling of patient responses from the optimized lymphodepletion arm (arm c) show consistent p-bcma-allo1 cellular expansion and persistence across subgroups new preclinical data supports p-cd19cd20-allo1's strong anti-cancer profile and the ongoing phase 1 clinical trial case study demonstrates reactivation of an autologous poseida car-t therapy with a t-cell engager in patient with relapsed multiple myeloma, highlighting potential of tscm-based car-t therapies to deliver a strong anti-myeloma response with long-term remission and car-t cell persistence san diego , dec. 9, 2024 /prnewswire/ -- poseida therapeutics, inc. (nasdaq: pstx), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today will highlight interim clinical data from its phase 1 trial of p-bcma-allo1 in patients with relapsed/refractory multiple myeloma (rrmm), including new profiling of patient responses from arm c, an optimized lymphodepletion arm. the p-bcma-allo1 data are being presented, along with two additional company poster presentations covering new preclinical data for p-cd19cd20-allo1 and a patient case study demonstrating the reactivation of a poseida autologous car-t therapy with a t-cell engager, at the 66th ash annual meeting and exposition being held in san diego on december 7-10, 2024.
ASH Ratings Summary
ASH Quant Ranking